AU2016253957C1 - High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells - Google Patents

High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells Download PDF

Info

Publication number
AU2016253957C1
AU2016253957C1 AU2016253957A AU2016253957A AU2016253957C1 AU 2016253957 C1 AU2016253957 C1 AU 2016253957C1 AU 2016253957 A AU2016253957 A AU 2016253957A AU 2016253957 A AU2016253957 A AU 2016253957A AU 2016253957 C1 AU2016253957 C1 AU 2016253957C1
Authority
AU
Australia
Prior art keywords
cells
agent
domain peptide
profiling
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016253957A
Other languages
English (en)
Other versions
AU2016253957B2 (en
AU2016253957A1 (en
Inventor
Patrick BHOLA
Anthony Letai
Jeremy RYAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2016253957A1 publication Critical patent/AU2016253957A1/en
Publication of AU2016253957B2 publication Critical patent/AU2016253957B2/en
Application granted granted Critical
Publication of AU2016253957C1 publication Critical patent/AU2016253957C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2016253957A 2015-04-27 2016-04-27 High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells Active AU2016253957C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562153475P 2015-04-27 2015-04-27
US62/153,475 2015-04-27
PCT/US2016/029495 WO2016176288A1 (en) 2015-04-27 2016-04-27 High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells

Publications (3)

Publication Number Publication Date
AU2016253957A1 AU2016253957A1 (en) 2017-10-19
AU2016253957B2 AU2016253957B2 (en) 2020-10-22
AU2016253957C1 true AU2016253957C1 (en) 2021-04-01

Family

ID=57198812

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016253957A Active AU2016253957C1 (en) 2015-04-27 2016-04-27 High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells
AU2016255749A Active AU2016255749B2 (en) 2015-04-27 2016-04-27 Compositions and methods for assessing toxicity using Dynamic BH3 profiling

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016255749A Active AU2016255749B2 (en) 2015-04-27 2016-04-27 Compositions and methods for assessing toxicity using Dynamic BH3 profiling

Country Status (6)

Country Link
US (4) US10761086B2 (enExample)
EP (2) EP3288964B1 (enExample)
JP (3) JP6802185B2 (enExample)
AU (2) AU2016253957C1 (enExample)
CA (1) CA2983022C (enExample)
WO (2) WO2016176299A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003267124A1 (en) 2002-09-09 2004-03-29 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
EP2008106A2 (en) 2006-03-31 2008-12-31 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
WO2014047342A1 (en) * 2012-09-19 2014-03-27 Dana-Farber Cancer Institute, Inc. Dynamic bh3 profiling
EP3047276B1 (en) 2013-09-19 2023-06-14 Dana-Farber Cancer Institute, Inc. Methods of bh3 profiling
EP3245301B1 (en) 2015-01-12 2020-11-11 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
US11142554B2 (en) 2015-03-18 2021-10-12 Massachusetts Institute Of Technology Selective Mcl-1 binding peptides
EP3611506B1 (en) 2015-04-20 2021-11-17 Sumitomo Dainippon Pharma Oncology, Inc. Predicting response to alvocidib by mitochondrial profiling
WO2016176299A1 (en) 2015-04-27 2016-11-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for assessing toxicity using dynamic bh3 profiling
PL3298021T3 (pl) 2015-05-18 2019-11-29 Tolero Pharmaceuticals Inc Proleki alvocidibu o zwiększonej biodostępności
WO2017024073A1 (en) 2015-08-03 2017-02-09 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
US11198715B2 (en) 2016-07-22 2021-12-14 Massachusetts Institute Of Technology Selective Bfl-1 peptides
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
KR20190099260A (ko) * 2016-12-19 2019-08-26 톨레로 파마수티컬스, 인크. 프로파일링 펩티드 및 감도 프로파일링을 위한 방법
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
WO2020060975A1 (en) * 2018-09-17 2020-03-26 Massachusetts Institute Of Technology Peptides selective for bcl-2 family proteins
JP2022511029A (ja) 2018-12-04 2022-01-28 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド がんの処置のための薬剤としての使用のためのｃｄｋ９インヒビターおよびその多形
EP3931563A4 (en) * 2019-02-26 2022-12-21 Dana-Farber Cancer Institute, Inc. BH3 DYNAMIC PROFILING FOR LIVING CELL IMAGING
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
WO2025212653A1 (en) * 2024-04-01 2025-10-09 Dana-Farber Cancer Institute, Inc. Methods including bh3 profiling of car t cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080199890A1 (en) * 2006-03-31 2008-08-21 Anthony Letai Methods of Determining Cellular Chemosensitivity
WO2014047342A1 (en) * 2012-09-19 2014-03-27 Dana-Farber Cancer Institute, Inc. Dynamic bh3 profiling
WO2015042249A1 (en) * 2013-09-19 2015-03-26 Dana-Farber Cancer Institute, Inc. Methods of bh3 profiling

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69637147T2 (de) 1995-07-28 2008-03-06 Marie Curie Cancer Care Transportproteine und deren verwendungen
EP0799422A1 (en) * 1995-10-24 1997-10-08 Sangstat Medical Corporation Anti alpha-galactosyl screening technique
US5965703A (en) 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2304124A1 (en) 1997-09-17 1999-03-25 The Walter And Eliza Hall Institute Of Medical Research Bci-2-like protein bim and methods of use thereof
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1210098A1 (en) 1999-04-07 2002-06-05 Thomas Jefferson University Enhancement of peptide cellular uptake
WO2001012661A2 (en) 1999-08-16 2001-02-22 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, The National Institutes Of Health RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS
WO2002020568A2 (en) 2000-09-06 2002-03-14 Abbott Laboratories Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins
AU2002258399A1 (en) 2001-02-16 2002-09-19 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
WO2003040168A2 (en) 2001-11-06 2003-05-15 Enanta Pharmaceuticals, Inc. Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
WO2003055515A1 (en) * 2001-12-21 2003-07-10 Arius Research, Inc. Individualized anti-cancer antibodies
AU2003267124A1 (en) 2002-09-09 2004-03-29 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
WO2004083405A2 (en) * 2003-03-19 2004-09-30 Alfa Wassermann, Inc. Separation and accumulation of subcellular components, and proteins derived therefrom
WO2005044839A2 (en) 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
WO2006069186A2 (en) 2004-12-22 2006-06-29 The Ohio State Research Foundation Small molecule bcl-xl/bcl-2 binding inhibitors
JP2005130867A (ja) * 2005-02-16 2005-05-26 Mitokor ミトコンドリア内カルシウムを使用するスクリーニングアッセイ
WO2006099667A1 (en) 2005-03-21 2006-09-28 The Walter And Eliza Hall Institute Of Medical Research Prophylactic and therapeutic agents and uses therefor
WO2007016254A2 (en) 2005-07-27 2007-02-08 The Board Of Trustees Of The University Of Arkansas Antineoplastic activities of ellipticine and its derivatives
US8518635B2 (en) 2006-06-12 2013-08-27 The J. David Gladstone Institutes Regulation of protein activity by reversible acetylation
KR100786759B1 (ko) * 2006-07-07 2007-12-18 김현기 Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물
WO2008021484A2 (en) 2006-08-16 2008-02-21 Eutropics Pharmaceuticals Assay system to identify therapeutic agents
WO2008152405A2 (en) 2007-06-15 2008-12-18 The Queen's University Of Belfast Protein complexes comprising bh3 peptides and voltage dependent anion channel (vdac) peptides as well as uses thereof for the treatment of proliferative diseases
CN101854955B (zh) 2007-09-10 2012-07-18 马萨诸塞大学 靶向线粒体的抗肿瘤剂
WO2009042237A2 (en) 2007-09-26 2009-04-02 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
JP2009240173A (ja) * 2008-03-28 2009-10-22 Univ Of Tokushima パーキン蛋白の新規糖化因子
EP2440652B1 (en) * 2009-06-11 2019-11-27 Minerva Biotechnologies Corporation Methods for culturing stem and progenitor cells
WO2010147961A1 (en) 2009-06-15 2010-12-23 Precision Therapeutics, Inc. Methods and markers for predicting responses to chemotherapy
US20130122492A1 (en) 2011-11-14 2013-05-16 Kellbenx Inc. Detection, isolation and analysis of rare cells in biological fluids
JP2015519565A (ja) 2012-05-10 2015-07-09 ユートロピクス ファーマシューティカルズ， インコーポレイテッド がんに対する補助的機能診断テスト
US20150322479A1 (en) * 2012-06-20 2015-11-12 Cytospan Technologies Corporation Apparatus and method for quantification of replicative lifespan and observation of senescene
JP6327662B2 (ja) 2012-09-26 2018-05-23 学校法人藤田学園 細胞表面タンパクを抗原とする抗体を測定する方法
US20160178612A1 (en) 2013-07-18 2016-06-23 Eutropics Pharmaceuticals, Inc. Differential bh3 mitochondrial profiling
WO2016176299A1 (en) 2015-04-27 2016-11-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for assessing toxicity using dynamic bh3 profiling
US11092602B2 (en) 2015-07-06 2021-08-17 Whitehead Institute For Biomedical Research Methods and compositions relating to proteasome inhibitor resistance
EP3931563A4 (en) 2019-02-26 2022-12-21 Dana-Farber Cancer Institute, Inc. BH3 DYNAMIC PROFILING FOR LIVING CELL IMAGING

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080199890A1 (en) * 2006-03-31 2008-08-21 Anthony Letai Methods of Determining Cellular Chemosensitivity
WO2014047342A1 (en) * 2012-09-19 2014-03-27 Dana-Farber Cancer Institute, Inc. Dynamic bh3 profiling
WO2015042249A1 (en) * 2013-09-19 2015-03-26 Dana-Farber Cancer Institute, Inc. Methods of bh3 profiling

Also Published As

Publication number Publication date
US20180128813A1 (en) 2018-05-10
WO2016176288A1 (en) 2016-11-03
HK1252058A1 (en) 2019-05-10
AU2016255749B2 (en) 2021-10-14
US20210255167A1 (en) 2021-08-19
US10761086B2 (en) 2020-09-01
US11867688B2 (en) 2024-01-09
AU2016253957B2 (en) 2020-10-22
HK1252055A1 (en) 2019-05-10
EP3289094A4 (en) 2018-10-31
US20180120297A1 (en) 2018-05-03
JP6802185B2 (ja) 2020-12-16
AU2016253957A1 (en) 2017-10-19
AU2016255749A1 (en) 2017-10-19
EP3288964A1 (en) 2018-03-07
JP2018514210A (ja) 2018-06-07
JP6814745B2 (ja) 2021-01-20
JP2018520638A (ja) 2018-08-02
CA2983022A1 (en) 2016-11-03
EP3289094A1 (en) 2018-03-07
EP3289094B1 (en) 2024-06-05
CA2983024A1 (en) 2016-11-03
US20210041419A1 (en) 2021-02-11
EP3288964B1 (en) 2024-02-21
JP2021036915A (ja) 2021-03-11
CA2983022C (en) 2023-03-07
EP3288964A4 (en) 2018-10-31
WO2016176299A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
US11867688B2 (en) High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells
EP1392342B1 (en) Global analysis of protein activities using proteome chips
US12529692B2 (en) Live cell imaging dynamic BH3 profiling
Dimitrova-Paternoga et al. Validation and classification of RNA binding proteins identified by mRNA interactome capture
Head et al. Identification of small molecule-binding proteins in a native cellular environment by live-cell photoaffinity labeling
HK1252058B (en) High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells
Rees et al. Identification of the cis-molecular neighbours of the immune checkpoint protein B7-H4 in the breast cancer cell-line SK-BR-3 by proteomic proximity labelling
CA2983024C (en) Compositions and methods for assessing toxicity using dynamic bh3 profiling
KR101444995B1 (ko) 세포질 단백질의 단백질-단백질 상호작용을 확인하는 방법
HK1252055B (en) Compositions and methods for assessing toxicity using dynamic bh3 profiling
Mackintosh et al. Mining sarcomas by proteomics approaches: Ewing sarcoma on the spotlight
Rodríguez-Ulloa et al. The Combination of the CIGB-300 Anticancer Peptide and Cisplatin Modulates Proteins Related to Cell Survival, DNA Repair and Metastasis in a Lung Cancer Cell Line Model
EP2981616B1 (en) Solid phase transfection of proteins and nucleic acids
KR101432714B1 (ko) 벤조안트라센 오염 검출을 위한 마커 및 키트
US20070154962A1 (en) Bcl-2 promoted cell death

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 16 DEC 2020

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 16 DEC 2020

FGA Letters patent sealed or granted (standard patent)